EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Edgewise Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$37.92+0.73 (+1.96%)
Close on Oct 19, 2026
- Market cap
- $4.08B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$22.86 (+151.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $4.08B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.11
- Dividend yield
- –
- Free cash flow yield
- -3.89%
Fundamentals
- Net income
- -$197.22M
- EPS, diluted
- -$1.85
- Free cash flow
- -$158.83M
- Book value per share
- $4.16
- Diluted shares
- 108M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$218.90M
Net income
-$197.22M
EPS, diluted
-$1.85
Free cash flow
-$158.83M
Reported periodTrailing twelve months